Bayer AG / Merck & Co. Inc.

Acute Coronary Syndrome

Competitive Landscape

ACS secondary prevention and anti-ischemic therapy splits into five established MOA classes that a commercial lead should size against vericiguat's soluble guanylate cyclase (sGC) stimulator mechanism. Oral P2Y12 antiplatelets: ticagrelor (Brilinta/Brilique, AstraZeneca, FDA-approved; AZ FY2023 revenue $1.55B), prasugrel (Effient, Lilly/Daiichi Sankyo, FDA-approved, now largely generic), clopidogrel (Plavix, Sanofi/BMS, generic) — standard-of-care DAPT post-PCI per ACC/AHA guidelines. Factor Xa anticoagulants for dual-pathway inhibition: low-dose rivaroxaban (Xarelto 2.5mg BID, Bayer/J&J, FDA-approved for CAD/PAD post-COMPASS) — directly overlaps Bayer's cardiovascular franchise. Beta-blockers and RAAS inhibitors: metoprolol, carvedilol, lisinopril, sacubitril/valsartan (Entresto, Novartis, FDA-approved for HFrEF, FY2023 net sales $6.0B) — post-MI LV-dysfunction foundation. PCSK9 inhibitors / LDL-lowering: evolocumab (Repatha, Amgen), alirocumab (Praluent, Regeneron/Sanofi) — event-reduction post-ACS per FOURIER and ODYSSEY OUTCOMES. Soluble guanylate cyclase stimulator (vericiguat/Verquvo, Merck/Bayer, FDA-approved January 2021 for worsening HFrEF per VICTORIA trial): NOT approved in pure ACS — clinical failure in COMMANDER HF analog and lack of ACS-specific program position vericiguat as a post-hospitalization HFrEF adjunct, not a direct ACS therapeutic. Commercial threat to Merck/Bayer in ACS is minimal because Verquvo is not positioned as an ACS agent; the franchise competes in worsening HF.